Current and Future Roles of Adjuvant Endocrine Therapy in the Management of Early Carcinoma of the Breast

  • M. Baum
  • J. R. Benson
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 140)


The world overview of adjuvant trials for early breast cancer published in The Lancet in January 1992 (Early Breast Cancer Trialists’ Collaborative Group 1992) provided us with secure data to allow the rational employment of adjuvant systemic chemotherapy and endocrine therapy, but like the process of science in any other walk of life, in answering one set of questions, a new set of questions has emerged. Effectively therefore, the world overview also set the agenda for the next decade of clinical trials in the management of early breast cancer. A whole raft of new questions has been defined concerning the role of endocrine manipulation in both pre- and postmenopausal women.


Breast Cancer Early Breast Cancer Adjuvant Endocrine Therapy Operable Breast Cancer Adjuvant Tamoxifen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Badwe RA, Gregory WM, Cahudary MA et al. (1994) Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1: 1261–1264Google Scholar
  2. Benson JR, Wakefield LM, Sporn MB et al. (1993) Secretion of TGF/1 isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen (Abstr). Breast Cancer Res Treat 27 (1/2): 163Google Scholar
  3. Butta A, Maclennan K, Flanders KC, Sacks NPM, Smith I, Mackinna A, Dowsett M, Wakefield LM, Sporn MB, Colletta AA (1992) Induction of transforming growth factor betas in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261–4264PubMedGoogle Scholar
  4. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC (1991) Pyrrolidino-4-iodotamoxifen and 4-lodotamoxifen. New analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851–5955PubMedGoogle Scholar
  5. Colletta AA, Benson JR, Baum M (1994) Alternate mechanisms of action of antioestrogens. Breast Cancer Res Treat 31: 5–9PubMedCrossRefGoogle Scholar
  6. Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA (1992) Insulin-like growth factor-II over-expression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 6: 91–100PubMedCrossRefGoogle Scholar
  7. De Friend D, Blamey RE, Robertson JF, Walton P, Howell A (1993) Response to the pure anti-oestrogen ICI 182,780 after tamoxifem failure in advanced breast cancer (Abstr). Breast Cancer Res Treat 27 (1/2): 136Google Scholar
  8. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24 000 deaths among 75 000 women. Lancet 339(8784):1–15, 339 (8785): 71–85Google Scholar
  9. Fentiman IS, Gregory WM (1994) Peri-operative hormones and prognosis in breast cancer. Eur J Cancer 30A (12): 1892–1894CrossRefGoogle Scholar
  10. Fernö M, Baldetorp B, Borg A et al. (1994) Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 30A (14): 2042–2048CrossRefGoogle Scholar
  11. Fisher B, Gunduz N, Coyle J (1989) Presence of a growth-stimulating factor in serum following primary tumour removal in mice. Cancer Res 49: 1996–2001PubMedGoogle Scholar
  12. Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82: 4–6PubMedCrossRefGoogle Scholar
  13. Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82: 4–6PubMedCrossRefGoogle Scholar
  14. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature [Medicine] 1 (1): 27CrossRefGoogle Scholar
  15. Gagliardi A, Collins DC (1993) Inhibition of angiogenesis by anti-oestrogens. Cancer Res 53: 533–535PubMedGoogle Scholar
  16. Horak E, Harris AL (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120–1124PubMedCrossRefGoogle Scholar
  17. Hori A, Sasada R, Matsutani E et al. (1991) Suppression of solid tumour growth by immuno-neutralising monoclonal antibody against fibroblasts growth factor. Cancer Res 51: 6180–6184PubMedGoogle Scholar
  18. Huynh HT, Tetenes E, Wallace L, Pollack M (1993) In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53: 1727–1730PubMedGoogle Scholar
  19. Jordan VC (ed) (1994) Long-term tamoxifen therapy for breast cancer. University of Wisconsin Press, MadisonGoogle Scholar
  20. Jordan VC, Morrow M (1994) Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A (11): 1714–1721CrossRefGoogle Scholar
  21. Lippman ME (1994) New approaches in diagnosing and treating breast cancer. Conference organised by Cambridge Healthtech Institute, PhiladelphiaGoogle Scholar
  22. Myall Y, Shiu RPC, Bhaumick B (1984) Receptor binding and growth promoting activity of insulin-like growth factors in human breast cancer cells (T47D) in culture. Cancer Res 44: 5486–5490Google Scholar
  23. Nicholson RI, Walker KJ, Turkes A et al. (1985) Endocrinological and clinical aspects of LHRH action (ICI 118,630) in hormone dependent breast cancer. J Steroid Biochem 23: 843–847PubMedCrossRefGoogle Scholar
  24. Nolvadex Adjuvant Trial Organisation (1987) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 54: 608–611Google Scholar
  25. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy’s Hospital, London (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341 (8856): 1293–1298Google Scholar
  26. Shultz GS, Grant MB (1991) Neovascular growth factors. Eye 5: 178–180Google Scholar
  27. Steinberg KK, Tacker SB et al. (1991) Meta-analysis of the effect of oestrogen replacement therapy on risk of breast cancer. JAMA 265: 1985–1990PubMedCrossRefGoogle Scholar
  28. Tripathy D (1994) How long should adjuvant tamoxifen be continued? Oncology 8 (10): 25–30PubMedGoogle Scholar
  29. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure anti-oestrogen with clinical potential. Cancer Res 51: 3867–3873PubMedGoogle Scholar
  30. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumour angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 324: 1–8PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. Baum
    • 1
  • J. R. Benson
    • 1
  1. 1.The Royal Marsden HospitalLondonUK

Personalised recommendations